September 21, 2005

Fostering Innovation and Discovery in Biomedical Research

Author Affiliations

Author Affiliation: Howard Hughes Medical Institute, Chevy Chase, Md.

JAMA. 2005;294(11):1390-1393. doi:10.1001/jama.294.11.1390

In today’s scientific era, molecular research has paved the way for the development of pharmaceuticals that are improving the lives of millions of patients. The discovery of the human immunodeficiency retrovirus as the causative agent of AIDS led to the development of reverse transcriptase inhibitors such as zidovudine. Monoclonal antibodies directed against tumor necrosis factor α have changed the lives of many patients with rheumatoid arthritis. Imatinib mesylate, a specific inhibitor of the bcr-abl protein kinase, has transformed the prognosis for patients with chronic myeloid leukemia; and as drug-resistant variants arise, DNA sequencing can identify the mutations responsible and provide a rational basis for further drug development.1,2 In 2004 the first angiogenesis inhibitors were approved by the US Food and Drug Administration, in one case for treatment of metastatic colorectal cancer and in another for age-related macular degeneration.3,4 There is reason for optimism that this is just the beginning, and that the huge investments in molecular biology and genomics research made 10 to 30 years ago will provide an increasingly robust flow of new and effective medicines.

First Page Preview View Large
First page PDF preview
First page PDF preview